Brokers expect Bausch Health Companies Inc. (NYSE: BHC) to report earnings per share of $0.91

Brokerages predict that Bausch Health Companies Inc. (NYSE:BHC – Get a rating) will report earnings per share of $0.91 for the current quarter, Zacks reports. Four analysts released earnings estimates for Bausch Health Companies, with the highest EPS estimate of $1.09 and the lowest estimate of $0.76. Bausch Health Companies reported earnings per share of $0.98 in the same quarter last year, suggesting a negative 7.1% year-over-year growth rate. The company is due to announce its next earnings report on Monday, January 1.

On average, analysts expect Bausch Health Companies to report annual earnings of $4.06 per share for the current fiscal year, with EPS estimates ranging from $3.67 to $4.87. For next year, analysts expect the company to post earnings of $4.65 per share, with EPS estimates ranging from $4.09 to $5.11. Zacks’ EPS calculations are an average average based on a survey of sell-side analysts who track Bausch Health Companies.

Bausch Health Companies (NYSE: BHC – Get a rating) last announced its results on Tuesday, May 10. The company reported earnings per share (EPS) of $0.72 for the quarter, missing the consensus estimate of $1.03 per ($0.31). Bausch Health Companies had a negative return on equity of 649.29% and a negative net margin of 4.89%. The company posted revenue of $1.92 billion for the quarter, versus analyst estimates of $2.06 billion.

The BHC has been the subject of several reports by research analysts. BMO Capital Markets cut its price target on shares of Bausch Health Companies from $26.00 to $15.00 in a Wednesday, May 11 report. Piper Sandler cut her price target on Bausch Health Companies stock from $27.00 to $7.00 in a Thursday, May 26 research note. StockNews.com downgraded shares of Bausch Health Companies from a “buy” rating to a “hold” rating in a Wednesday, May 11 research note. TheStreet downgraded shares of Bausch Health Companies from a “c-” rating to a “d+” rating in a Monday, March 28 research note. Finally, Royal Bank of Canada cut its price target on Bausch Health Companies shares from $21.00 to $17.00 and set an “outperform” rating on the stock in a Sunday research note. May 15. Two investment analysts gave the stock a hold rating and five gave the company a buy rating. According to MarketBeat.com, the stock currently has a consensus buy rating and a consensus target price of $18.50.

Separately, insider Robert Spurr sold 1,595 shares in a trade on Thursday, April 14. The stock was sold at an average price of $22.19, for a total transaction of $35,393.05. Following the completion of the sale, the insider now directly owns 90,506 shares of the company, valued at $2,008,328.14. The sale was disclosed in a filing with the SEC, which is available via the SEC website. 13.75% of the shares are held by insiders of the company.

Major investors have recently increased or reduced their stakes in the company. WASHINGTON TRUST Co bought a new stock position in Bausch Health Companies in the first quarter worth $28,000. Creative Financial Designs Inc. ADV increased its position in shares of Bausch Health Companies by 525.0% in the first quarter. Creative Financial Designs Inc. ADV now owns 1,250 shares of the company valued at $29,000 after purchasing an additional 1,050 shares in the last quarter. Amplius Wealth Advisors LLC bought a new stock position in Bausch Health Companies in the fourth quarter worth $30,000. Glassman Wealth Services increased its position in shares of Bausch Health Companies by 71.4% in the fourth quarter. Glassman Wealth Services now owns 1,152 shares of the company valued at $32,000 after buying an additional 480 shares last quarter. Finally, Sargent Bickham Lagudis LLC bought a new stock position in Bausch Health Companies in the first quarter worth $57,000. Hedge funds and other institutional investors own 73.38% of the company’s shares.

BHC shares were down $0.35 on Friday, hitting $8.03. 6,260,544 shares of the stock have been traded, compared to its average volume of 5,613,985. The company’s 50-day moving average price is $15.47 and its two-hundred-day moving average price is of $21.57. The stock has a market capitalization of $2.90 billion, a PE ratio of -7.04, a PEG ratio of 0.20 and a beta of 1.66. Bausch Health Companies has a 12-month low of $7.80 and a 12-month high of $32.08.

About Bausch Healthcare Companies (Get a rating)

Bausch Health Companies Inc, together with its subsidiaries, develops, manufactures and markets a range of pharmaceutical, medical device and over-the-counter products primarily in the therapeutic areas of eye health, gastroenterology and dermatology. The Company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics and Diversified Products.

Featured Articles

Get a Free Copy of Zacks Research Report on Bausch Health Companies (BHC)

For more information on Zacks Investment Research’s research offerings, visit Zacks.com

This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]

Should you invest $1,000 in Bausch Health Companies right now?

Before you consider Bausch Health Companies, you’ll want to hear this.

MarketBeat tracks Wall Street’s top-rated, top-performing research analysts daily and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and Bausch Health Companies was not on the list.

Although Bausch Health Companies currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the 5 actions here